Gateway Investment Advisers LLC Sells 843 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gateway Investment Advisers LLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 6,540 shares of the biopharmaceutical company's stock after selling 843 shares during the period. Gateway Investment Advisers LLC's holdings in Alnylam Pharmaceuticals were worth $1,766,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Whipplewood Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $28,000. Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer now owns 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. UBS Group increased their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, Royal Bank of Canada raised their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ ALNY traded down $3.88 during mid-day trading on Wednesday, hitting $298.58. The company's stock had a trading volume of 454,983 shares, compared to its average volume of 930,235. The stock has a market cap of $38.93 billion, a price-to-earnings ratio of -137.59 and a beta of 0.22. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a one year low of $152.30 and a one year high of $313.79. The company's fifty day simple moving average is $266.98 and its 200-day simple moving average is $258.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. The company's revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.16) earnings per share. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.